Since the beginning of the year Recordati has recorded a net profit of 92 million euros, +5,8% compared to the same period of 2010. Consolidated net revenues were 580,6 million euros.
The financial position includes a net debt of 29,3 million euros, due in part to the acquisition of the Turkish Frik Llac, the shareholders' equity rose to 606,3 million. The pharmaceutical company has also announced a change in its shareholder remuneration policy: an interim dividend will be paid starting from the current year. Giovanni Recordati reiterated his objectives for 2011: "revenues of over 750 million, an operating profit of over 160 million and a net profit of 110 million".
